Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability
- Author
- WIDMER, N1 ; DECOSTERD, L. A1 ; LEYVRAZ, S2 ; DUCHOSAL, M. A3 ; ROSSELET, A3 ; DEBIEC-RYCHTER, M4 ; CSAJKA, C1 ; BIOLLAZ, J1 ; BUCLIN, T1
[1] Division of Clinical Pharmacology, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
[2] Multidisdplinary Oncology Centre, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
[3] Service of Haematology, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
[4] Department of Human Genetics, University of Leuven and University Hospital Gasthuisberg, Leuven, Belgium - Source
British journal of cancer. 2008, Vol 98, Num 10, pp 1633-1640, 8 p ; ref : 1 p.1/2
- CODEN
- BJCAAI
- ISSN
- 0007-0920
- Scientific domain
- Medical oncology
- Publisher
- Nature Publishing Group, Basingstoke
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- imatinib leukaemia pharmacogenetics pharmacokinetics and pharmacodynamics sarcoma signal transduction inhibitors
- Keyword (fr)
- Anticancéreux Cancérologie Ciblage Efficacité traitement Génotype Imatinib Inhibiteur enzyme Leucémie Pharmacocinétique Pharmacogénétique Plasma sanguin Protein-tyrosine kinase Sarcome Transduction signal Pharmacodynamie Cancer Enzyme Génétique Hémopathie maligne Inhibiteur de la tyrosine kinase Transferases Tumeur maligne
- Keyword (en)
- Antineoplastic agent Cancerology Targeting Treatment efficiency Genotype Imatinib Enzyme inhibitor Leukemia Pharmacokinetics Pharmacogenetics Blood plasma Protein-tyrosine kinase Sarcoma Signal transduction Pharmacodynamics Cancer Enzyme Genetics Malignant hemopathy Tyrosine kinase inhibitor Transferases Malignant tumor
- Keyword (es)
- Anticanceroso Cancerología Blancado Eficacia tratamiento Genotipo Imatinib Inhibidor enzima Leucemia Farmacocinética Farmacogenética Plasma sanguíneo Protein-tyrosine kinase Sarcoma Transducción señal Farmacodinámica Cáncer Enzima Genética Hemopatía maligna Inhibidor tyrosine kinase Transferases Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B19 Hematologic and hematopoietic diseases / 002B19B Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
- Discipline
- Blood diseases Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 20374136
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1038/sj.bjc.6604355 
https://dx.doi.org/10.1038/sj.bjc.6604355
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjc.6604355\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:94:\"Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. J. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"98\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"1633\";s:8:\"\u0000*\u0000epage\";s:4:\"1640\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"WIDMER\";s:10:\"\u0000*\u0000aufirst\";s:1:\"N\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:15:\"DECOSTERD, L. A\";i:1;s:10:\"LEYVRAZ, S\";i:2;s:14:\"DUCHOSAL, M. A\";i:3;s:11:\"ROSSELET, A\";i:4;s:17:\"DEBIEC-RYCHTER, M\";i:5;s:9:\"CSAJKA, C\";i:6;s:10:\"BIOLLAZ, J\";i:7;s:9:\"BUCLIN, T\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:94:\"Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjc.6604355\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:94:\"Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. J. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"98\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"1633\";s:8:\"\u0000*\u0000epage\";s:4:\"1640\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"WIDMER\";s:10:\"\u0000*\u0000aufirst\";s:1:\"N\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:15:\"DECOSTERD, L. A\";i:1;s:10:\"LEYVRAZ, S\";i:2;s:14:\"DUCHOSAL, M. A\";i:3;s:11:\"ROSSELET, A\";i:4;s:17:\"DEBIEC-RYCHTER, M\";i:5;s:9:\"CSAJKA, C\";i:6;s:10:\"BIOLLAZ, J\";i:7;s:9:\"BUCLIN, T\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:94:\"Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjc.6604355\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjc.6604355\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:94:\"Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. J. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"98\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"1633\";s:8:\"\u0000*\u0000epage\";s:4:\"1640\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"WIDMER\";s:10:\"\u0000*\u0000aufirst\";s:1:\"N\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:15:\"DECOSTERD, L. A\";i:1;s:10:\"LEYVRAZ, S\";i:2;s:14:\"DUCHOSAL, M. A\";i:3;s:11:\"ROSSELET, A\";i:4;s:17:\"DEBIEC-RYCHTER, M\";i:5;s:9:\"CSAJKA, C\";i:6;s:10:\"BIOLLAZ, J\";i:7;s:9:\"BUCLIN, T\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:94:\"Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjc.6604355\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:94:\"Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. J. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"98\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"1633\";s:8:\"\u0000*\u0000epage\";s:4:\"1640\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"WIDMER\";s:10:\"\u0000*\u0000aufirst\";s:1:\"N\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:15:\"DECOSTERD, L. A\";i:1;s:10:\"LEYVRAZ, S\";i:2;s:14:\"DUCHOSAL, M. A\";i:3;s:11:\"ROSSELET, A\";i:4;s:17:\"DEBIEC-RYCHTER, M\";i:5;s:9:\"CSAJKA, C\";i:6;s:10:\"BIOLLAZ, J\";i:7;s:9:\"BUCLIN, T\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:94:\"Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjc.6604355\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:94:\"Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. J. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"98\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"1633\";s:8:\"\u0000*\u0000epage\";s:4:\"1640\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"WIDMER\";s:10:\"\u0000*\u0000aufirst\";s:1:\"N\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:15:\"DECOSTERD, L. A\";i:1;s:10:\"LEYVRAZ, S\";i:2;s:14:\"DUCHOSAL, M. A\";i:3;s:11:\"ROSSELET, A\";i:4;s:17:\"DEBIEC-RYCHTER, M\";i:5;s:9:\"CSAJKA, C\";i:6;s:10:\"BIOLLAZ, J\";i:7;s:9:\"BUCLIN, T\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:94:\"Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
